Table 1 Main characteristics of study participants
From: Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults
Variable | N = 99 |
|---|---|
Age (years) | 15.3 [IQR:13.6-16.7] |
Ethnicity | |
Caucasian | 83 (85.6) |
African | 5 (5.1) |
Hispanic | 2 (2.1) |
Roma | 2 (2.1) |
Other | 5 (5.1) |
Female | 57(57.6) |
CDC clinical stage | |
A | 25 (25.5) |
B | 29 (29.6) |
C | 44 (44.9) |
CDC immunological stage | |
1 | 2 (2.1) |
2 | 31 (31.3) |
3 | 66 (66.6) |
Tanner stage | |
1 | 4(4.1) |
2 | 8 (8.1) |
3 | 14 (14.1) |
4 | 18 (18.1) |
5 | 55(55.6) |
Weight (kg) | 51.1 [44.7-59.2] |
Weight Z score | −0.2 [−0.79-0.76] |
Height (cm) | 160 [153.5-166.9] |
Height Z score | −0.03 [−1-0.7] |
BMI | 19.9 [18.3-22.3] |
Age at menarche (years) | 12.0 [11.7-13.0] |
Treatment | |
HAART | 92 (92.9) |
No treatment | 7 (7.1) |
Total ARV exposure (years) | 11.4 [9.1-12.8] |
HAART exposure (years) | 9.4 [6.7-10.7] |
PI exposure (months) | 90.4 [44.1-127.8] |
NNRTI exposure (months) | 39.8[3.3-85.7] |
Type of treatment | |
2 NRTIs + 1 PI | 35 (38.1) |
2 NRTIs + 1 NNRTI | 28 (30.4) |
2 NRTIs + 1 PI +1 NNRTI | 21 (22.8) |
Other | 8 (8.7) |
Viral load (copies/ml) | 50 [50–200] |
Viral load (<50 copies/ml) | 66 (66.7) |
CD4 count (cs/mm 3 ) | 737.0 [503.8-975.5] |
CD4 % | 33 [25.4-38.5] |
CD4 nadir (cs/mm 3 ) | 252 [102–442] |